Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Maintenance treatment with antipsychotic drugs for schizophrenia.
- S. Leucht, M. Tardy, K. Komossa, S. Heres, Werner Kissling, John M. Davis
- Medicine
- The Cochrane database of systematic reviews
- 16 May 2012
BACKGROUND
The symptoms and signs of schizophrenia have been firmly linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of… Expand
Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.
IMPORTANCE
There is debate about the effectiveness of psychiatric treatments and whether pharmacotherapy or psychotherapy should be primarily used.
OBJECTIVES
To perform a systematic overview on… Expand
Benzodiazepines for schizophrenia.
- M. Dold, C. Li, M. Tardy, V. Khorsand, D. Gillies, S. Leucht
- Medicine
- The Cochrane database of systematic reviews
- 14 November 2012
BACKGROUND
Because of the high number of people with schizophrenia not responding adequately to monotherapy with antipsychotic agents, the evidence regarding the efficacy and safety of additional… Expand
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
- M. Tardy, M. Huhn, Werner Kissling, R. Engel, S. Leucht
- Medicine
- The Cochrane database of systematic reviews
- 9 July 2014
BACKGROUND
Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic compounds, however, low-potency… Expand
Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.
BACKGROUND
Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic drugs, however, low-potency… Expand
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
- M. Dold, M. Samara, C. Li, M. Tardy, S. Leucht
- Medicine
- The Cochrane database of systematic reviews
- 16 January 2015
BACKGROUND
Haloperidol is worldwide one of the most frequently used antipsychotic drugs with a very high market share. Previous narrative, unsystematic reviews found no differences in terms of… Expand
Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
BACKGROUND
Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however,… Expand
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
BACKGROUND
Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however,… Expand
Subjective sleep and cognitive complaints in 65 year old subjects: A significant association. The PROOF cohort
- M. Tardy, R. Gonthier, J. Barthélémy, F. Roche, É. Crawford-Achour
- Medicine
- The journal of nutrition, health & aging
- 1 April 2015
ObjectiveThe prevalence of subjective sleep and cognitive complaints increases with age. The purpose of this study was to investigate the link between subjective cognitive and sleep complaints in a… Expand
Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials
- M. Dold, M. Tardy, M. Samara, C. Li, S. Kasper, S. Leucht
- Psychology, Medicine
- The world journal of biological psychiatry : the…
- 26 February 2016
Abstract Objectives: Narrative, unsystematic reviews revealed no differences in efficacy between the various first-generation antipsychotics (FGAs) resulting in the psychopharmacological assumption… Expand